⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4409585 | 0.67 | GSK3A (0.32) | — | |
| SCHEMBL4409586 | 0.65 | ADRA2C (0.35) | — | |
| SCHEMBL16660165 | 0.65 | — | — | |
| SCHEMBL2138759 | 0.62 | — | — | |
| SCHEMBL735080 | 0.61 | — | — | |
| SCHEMBL2206771 | 0.61 | — | — | |
| SCHEMBL16694952 | 0.59 | — | — | |
| SCHEMBL3092227 | 0.59 | — | — | |
| SCHEMBL4407950 | 0.56 | BRD4 (0.38) | — | |
| SCHEMBL7663866 | 0.56 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 150 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7358265-B2 | Oxa-and thiadiazoles and their use as metalloproteinase inhibitors | VERNALIS (R&D) LTD | 2008-04-15 | — | — | US | claimed |
| EP-1476438-B1 | OXA- AND THIADIAZOLES AND THEIR USE AS METALLOPROTEINASE INHIBITORS | VERNALIS R&D LTD (GB) | 2007-04-18 | — | — | EP | claimed |
| US-20050222189-A1 | Oxa-and thiadiazoles and their use as metalloproteinase inhibitors | VERNALIS (OXFORD) LTD (GB) | 2005-10-06 | — | — | US | claimed |
| US-6790834-B1 | Cytostatic agents | BRITISH BIOTECH PHARMACEUTICALS, LTD. (GB) | 2004-09-14 | — | — | US | claimed |
| US-20030149084-A1 | Cytostatic agents | AYSCOUGH ANDREW PAUL (GB) | 2003-08-07 | — | — | US | claimed |
| EP-0865339-B1 | METALLOPROTEINASE INHIBITORS | BRITISH BIOTECH PHARM (GB) | 2003-01-22 | — | — | EP | claimed |
| EP-0925278-B1 | CYTOSTATIC HYDROXAMIC ACID DERIVATIVES | BRITISH BIOTECH PHARM (GB) | 2002-07-17 | — | — | EP | claimed |
| US-20020052511-A1 | Process for the preparation of matrix metalloproteinase inhibitors | BAILEY ANNE E (US) | 2002-05-02 | — | — | US | claimed |
| EP-0944587-B1 | METALLOPROTEINASE INHIBITORS | BRITISH BIOTECH PHARM (GB) | 2002-03-20 | — | — | EP | claimed |
| US-20020019539-A1 | Process for the preparation of matrix metalloproteinase inhibitors | ABBOTT LABORATORIES | 2002-02-14 | — | — | US | claimed |
| US-6306881-B1 | ENZYME INHIBITORS ADMINISTERED TO MAMMALS AS ANTIINFLAMMATORY AGENTS | BRITISH BIOTECH PHARMACEUTICALS (GB) | 2001-10-23 | — | — | US | claimed |
| US-6258851-B1 | ENZYME INHIBITORS OF PROTEASES OR METALLOENZYMES | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 2001-07-10 | — | — | US | claimed |
| US-6251940-B1 | ADMINISTERING TO THE MAMMAL SUFFERING FROM A DISEASES RESPONSIVE TO INHIBIT MONOCYTE AND/OR MACROPHASE AND/OR LYMPHOCYTE ACTIVATION AND OF LYMPHOCYTE PROLIFERATION AN AMIDE DERIVATIVE | BRITISH BIOTECH PHARMACEUTICALS LTD. (GB) | 2001-06-26 | — | — | US | claimed |
| US-6232059-B1 | ORGANIC SILVER SALT, A REDUCING AGENT, AND A SPECIFIC NUCLEATING AGENT; HIGH DMAX, HIGH SENSITIVITY, SATISFACTORY CONTRAST, LOW FOG, AND MINIMAL DEPENDENCY OF PHOTOGRAPHIC PROPERTIES ON DEVELOPING TEMPERATURE | FUJI PHOTO FILM CO., LTD. (JP) | 2001-05-15 | — | — | US | claimed |
| US-6169075-B1 | ANTITUMOR AGENT INHIBITING THE PROLIFERATION OF A RANGE OF RAPIDLY DIVIDING TUMOUR CELLS LIKE MELANOMA AND/OR LYMPHOMA CELLS | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 2001-01-02 | — | — | US | claimed |
| US-5840974-A | Metalloproteinase inhibitors | BRITISCH BIOTECH PHARMACEUTICALS, LTD. (GB) | 1998-11-24 | — | — | US | claimed |
| EP-0574758-B1 | Hydroxamic acid derivatives as collagenase inhibitors | HOFFMANN LA ROCHE (CH) | 1998-09-09 | — | — | EP | claimed |
| US-5447929-A | Collagenase inhibitors for degenerative joint disease, antitumor agents or atherosclerosis | HOFFMANN-LA ROCHE INC. (US) | 1995-09-05 | — | — | US | claimed |
| US-5318964-A | Collangenase inhibitors; antiarthritic and -tumor agents; rheumatic diseases; osteoarthritis; atherosclerosis; multiple sclerosis | HOFFMANN-LA ROCHE INC. (US) | 1994-06-07 | — | — | US | claimed |
| EP-0574758-A1 | Hydroxamic acid derivatives as collagenase inhibitors | F. HOFFMANN-LA ROCHE AG (CH) | 1993-12-22 | — | — | EP | claimed |